JP2013056930A5 - - Google Patents

Download PDF

Info

Publication number
JP2013056930A5
JP2013056930A5 JP2012257150A JP2012257150A JP2013056930A5 JP 2013056930 A5 JP2013056930 A5 JP 2013056930A5 JP 2012257150 A JP2012257150 A JP 2012257150A JP 2012257150 A JP2012257150 A JP 2012257150A JP 2013056930 A5 JP2013056930 A5 JP 2013056930A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
substituted
unsubstituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012257150A
Other languages
English (en)
Japanese (ja)
Other versions
JP5814903B2 (ja
JP2013056930A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013056930A publication Critical patent/JP2013056930A/ja
Publication of JP2013056930A5 publication Critical patent/JP2013056930A5/ja
Application granted granted Critical
Publication of JP5814903B2 publication Critical patent/JP5814903B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012257150A 2005-11-01 2012-11-26 キナーゼのビ−アリールメタ−ピリミジン阻害剤 Active JP5814903B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73262905P 2005-11-01 2005-11-01
US60/732,629 2005-11-01
US83800306P 2006-08-15 2006-08-15
US60/838,003 2006-08-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008538935A Division JP5191391B2 (ja) 2005-11-01 2006-10-26 キナーゼのビ−アリールメタ−ピリミジン阻害剤

Publications (3)

Publication Number Publication Date
JP2013056930A JP2013056930A (ja) 2013-03-28
JP2013056930A5 true JP2013056930A5 (https=) 2013-05-30
JP5814903B2 JP5814903B2 (ja) 2015-11-17

Family

ID=38006192

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008538935A Active JP5191391B2 (ja) 2005-11-01 2006-10-26 キナーゼのビ−アリールメタ−ピリミジン阻害剤
JP2012257150A Active JP5814903B2 (ja) 2005-11-01 2012-11-26 キナーゼのビ−アリールメタ−ピリミジン阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008538935A Active JP5191391B2 (ja) 2005-11-01 2006-10-26 キナーゼのビ−アリールメタ−ピリミジン阻害剤

Country Status (27)

Country Link
US (3) US7528143B2 (https=)
EP (1) EP1951684B1 (https=)
JP (2) JP5191391B2 (https=)
KR (2) KR101494468B1 (https=)
CN (1) CN103626742B (https=)
AU (1) AU2006309013B2 (https=)
BE (1) BE2021C513I2 (https=)
BR (3) BRPI0618179A2 (https=)
CA (1) CA2628283C (https=)
CY (2) CY1118330T1 (https=)
DK (1) DK1951684T3 (https=)
ES (1) ES2595636T3 (https=)
FI (1) FIC20210010I1 (https=)
FR (1) FR21C1019I2 (https=)
HU (2) HUE028987T2 (https=)
IL (1) IL191167A (https=)
LT (2) LT1951684T (https=)
MX (2) MX362412B (https=)
MY (1) MY167260A (https=)
NL (1) NL301104I2 (https=)
NO (1) NO342221B1 (https=)
NZ (2) NZ567851A (https=)
PL (1) PL1951684T3 (https=)
PT (1) PT1951684T (https=)
RU (2) RU2589878C2 (https=)
TW (1) TWI444368B (https=)
WO (1) WO2007053452A1 (https=)

Families Citing this family (345)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
KR20120032574A (ko) * 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
KR20070011458A (ko) * 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
PL382308A1 (pl) * 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ563984A (en) * 2005-06-08 2011-11-25 Targegen Inc Methods and compositions for the treatment of ocular disorders
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US20070149508A1 (en) * 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7691858B2 (en) * 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
US8030487B2 (en) * 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
CN101535276B (zh) 2006-10-23 2013-08-28 赛福伦公司 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物
EP2097376A2 (en) 2006-12-22 2009-09-09 F. Hoffmann-Roche AG Spiro-piperidine derivatives
TW200840581A (en) * 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
MX2009009117A (es) * 2007-03-01 2009-09-03 Supergen Inc Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
US7947698B2 (en) * 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
EP2183242A2 (en) * 2007-07-16 2010-05-12 AstraZeneca AB Pyrimidine derivatives 934
CA2693594A1 (en) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
EA017252B1 (ru) 2007-08-28 2012-11-30 Айрм Ллк Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
WO2009073575A2 (en) * 2007-11-30 2009-06-11 Oregon Health & Science University Methods for treating induced cellular proliferative disorders
ES2375919T3 (es) 2008-01-11 2012-03-07 F. Hoffmann-La Roche Ag Moduladores de beta-amiloide.
MX2010008700A (es) * 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
PL2252300T3 (pl) 2008-02-22 2017-04-28 Rigel Pharmaceuticals, Inc. Zastosowanie 2,4-pirymidynodiamin do leczenia miażdżycy
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US20100029675A1 (en) * 2008-07-25 2010-02-04 Hwang Soo-In Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
MX2011001426A (es) * 2008-08-05 2011-03-21 Targegen Inc Metodos para tratar la talasemia.
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
ES2429517T3 (es) 2008-10-09 2013-11-15 F. Hoffmann-La Roche Ag Moduladores para la beta amiloide
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
US20110245156A1 (en) * 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
CA2752150A1 (en) 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
EP2414337B1 (en) * 2009-04-03 2013-05-01 Cellzome GmbH Methods for the identification of kinase interacting molecules and for the purification of kinase proteins
US20120040955A1 (en) * 2009-04-14 2012-02-16 Richard John Harrison Fluoro substituted pyrimidine compounds as jak3 inhibitors
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
AR076550A1 (es) * 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
JP5775070B2 (ja) * 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
SG176111A1 (en) * 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PT2473049T (pt) 2009-09-04 2019-03-04 Sunesis Pharmaceuticals Inc Inibidores de tirosina quinase de bruton
EP2475648A1 (en) * 2009-09-11 2012-07-18 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
NZ620174A (en) 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
CA2776028C (en) * 2009-10-15 2015-12-01 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
WO2011056739A1 (en) * 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
AU2010315361B2 (en) 2009-11-03 2014-06-12 Glaxosmithkline Llc Quinazoline compounds
AU2010333024B2 (en) * 2009-12-14 2014-09-18 Merck Sharp & Dohme B.V. MK2 inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
ES2461967T3 (es) 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
TWI487697B (zh) * 2009-12-23 2015-06-11 Palau Pharma Sa 作為組織胺ｈ受體拮抗劑之胺基烷基嘧啶衍生物類
EP2519664A4 (en) 2009-12-30 2014-03-12 Avila Therapeutics Inc LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
JP2013517273A (ja) * 2010-01-13 2013-05-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 化合物および方法
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
CN102821759A (zh) 2010-03-30 2012-12-12 诺华有限公司 用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
WO2011149827A1 (en) * 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
CN105566229A (zh) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐及其用途和制备方法
MX382354B (es) 2010-11-01 2025-03-13 Celgene Car Llc Compuestos heterocíclicos y usos de los mismos.
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9108984B2 (en) * 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
WO2012135009A1 (en) * 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
WO2012135641A2 (en) 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof
EP2694486B1 (en) 2011-04-01 2018-01-10 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
BR112013025387B1 (pt) * 2011-04-01 2021-07-27 University Of Utah Research Foundation Compostos análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl, uso dos ditos compostos para o tratamento de um distúrbio de proliferação celular descontrolada, bem como kit compreendendo ditos compostos
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013059548A1 (en) 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
CN102429901B (zh) * 2011-11-03 2013-11-06 合肥博太医药生物技术发展有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备防治肾纤维化药物中的应用
KR102081042B1 (ko) 2012-03-15 2020-02-26 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 고체 형태
PL2825042T3 (pl) 2012-03-15 2019-02-28 Celgene Car Llc Sole inhibitora kinazy receptora czynnika wzrostu naskórka
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9353087B2 (en) * 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014055928A2 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9296703B2 (en) 2012-10-04 2016-03-29 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
AU2014214846A1 (en) 2013-02-08 2015-07-23 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
WO2014151761A1 (en) * 2013-03-15 2014-09-25 Ariad Pharmaceuticals, Inc. Novel choline kinase inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9210831B2 (en) 2013-04-15 2015-12-08 International Business Machines Corporation Separable and integrated heat sinks facilitating cooling multi-compnent electronic assembly
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
WO2014195323A1 (en) * 2013-06-04 2014-12-11 Acturum Life Science AB Pyrimidine compounds and their use as gamma secretase modulators
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
US9850216B2 (en) * 2013-08-06 2017-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
EP3080103B9 (en) 2013-12-11 2018-09-19 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2936865A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
BR112016017045A2 (pt) 2014-01-31 2017-08-08 Dana Farber Cancer Inst Inc Derivados de diazepano e usos dos mesmos
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US10106507B2 (en) 2014-08-03 2018-10-23 H. Lee Moffitt Cancer Center and Research Insitute, Inc. Potent dual BRD4-kinase inhibitors as cancer therapeutics
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
KR20170032474A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
EP4578865A3 (en) 2014-08-12 2025-07-30 Monash University Lymph directing prodrugs
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
TWI679205B (zh) * 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
US10480375B2 (en) 2014-10-28 2019-11-19 Cummins Emission Solutions Inc. SCR conversion efficiency diagnostics
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EP3262049B1 (en) 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
SI3831833T1 (sl) 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR102591886B1 (ko) * 2015-07-21 2023-10-20 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
CA2997106C (en) 2015-09-08 2024-06-04 Monash University Lymph directing prodrugs
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
US10738016B2 (en) 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics
HUE061437T2 (hu) 2015-10-23 2023-06-28 Navitor Pharm Inc A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
GB201521919D0 (en) 2015-12-11 2016-01-27 Electrophoretics Ltd Isobaric mass labels
US11370792B2 (en) 2015-12-14 2022-06-28 Raze Therapeutics, Inc. Caffeine inhibitors of MTHFD2 and uses thereof
LT3426243T (lt) 2016-03-09 2021-08-10 Raze Therapeutics, Inc. 3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas
EP4234552A3 (en) 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
HUE064145T2 (hu) * 2016-04-15 2024-03-28 Epizyme Inc Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
EP3848370B1 (en) 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
EP3565638B8 (en) 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
JP7160824B2 (ja) 2017-03-08 2022-10-25 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤、使用およびその製造のための方法
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
US10342766B2 (en) * 2017-03-23 2019-07-09 North Carolina Agricultural And Technical State University 6-shogaol derivatives and activities thereof
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
US10912750B2 (en) 2017-04-26 2021-02-09 Navitor Pharmaceuticals, Inc. Modulators of Sestrin-GATOR2 interaction and uses thereof
WO2018197893A1 (en) 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
KR102717819B1 (ko) 2017-07-28 2024-10-14 다케다 야쿠힌 고교 가부시키가이샤 Tyk2 억제제 및 이의 용도
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP3675838A4 (en) 2017-08-29 2021-04-21 PureTech LYT, Inc. LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
CA3079273A1 (en) * 2017-10-18 2019-04-25 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN111892543A (zh) 2018-01-16 2020-11-06 深圳市塔吉瑞生物医药有限公司 用于抑制激酶活性的二苯氨基嘧啶类化合物
EP3746071A4 (en) 2018-01-29 2021-09-01 Merck Patent GmbH GCN2 INHIBITORS AND THEIR USES
KR20200116481A (ko) 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
EP3746430A4 (en) * 2018-02-02 2021-11-03 Padforward LLC INHIBITORS OF PROTEIN ARGININE DEIMINASES
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
KR20260028873A (ko) 2018-02-27 2026-03-04 아텍스 바이오파마 인코포레이티드 Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
CN112533602A (zh) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 Axl激酶抑制剂及其用途
KR102063155B1 (ko) 2018-04-11 2020-01-08 한국과학기술연구원 우수한 카이네이즈 저해 활성을 보이는 다양한 치환기를 갖는 피리미딘 유도체
ES2919572T3 (es) 2018-04-24 2022-07-27 Merck Patent Gmbh Compuestos antiproliferación y usos de los mismos
ES2969982T3 (es) 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
WO2020068755A1 (en) 2018-09-25 2020-04-02 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
JP7619951B2 (ja) 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CN113164414A (zh) 2018-10-24 2021-07-23 纳维托制药有限公司 多晶型化合物和其用途
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
JP7530360B2 (ja) 2018-11-30 2024-08-07 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
CN111362922A (zh) * 2018-12-26 2020-07-03 上海喆邺生物科技有限公司 2,4-二氨基嘧啶衍生物及其用途
CN120865208A (zh) 2019-01-23 2025-10-31 武田药品工业株式会社 Tyk2抑制剂和其用途
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR
FR3092581A1 (fr) * 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3937943A4 (en) 2019-03-15 2022-12-07 The General Hospital Corporation NEW SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
TWI875749B (zh) 2019-04-05 2025-03-11 美商凱麥拉醫療公司 Stat降解劑及其用途
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020257644A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2021091535A1 (en) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
WO2020256739A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP7842684B2 (ja) 2019-09-11 2026-04-08 ビンシア・バイオサイエンシーズ・インコーポレイテッド Ｕｓｐ３０阻害剤及びその使用
CN114945366B (zh) 2019-09-13 2025-01-07 林伯士萨顿公司 Hpk1拮抗剂和其用途
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11306062B2 (en) 2019-10-29 2022-04-19 Johnson Matthey Public Limited Forms of fedratinib dihydrochloride
CA3156436A1 (en) 2019-11-01 2021-05-06 Steven LEVENTER Methods of treatment using an mtorc1 modulator
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
KR20220128345A (ko) 2019-12-05 2022-09-20 아나쿠리아 테라퓨틱스, 인코포레이티드 라파마이신 유사체 및 이의 용도
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN111423419B (zh) * 2020-01-17 2021-12-17 温州医科大学 一种小分子化合物cyy-260及其在制备抗肿瘤药物中的应用
CN115348864A (zh) 2020-02-05 2022-11-15 纯技术Lyt股份有限公司 神经甾体的脂质前药
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
US12528785B2 (en) 2020-03-19 2026-01-20 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
CN113754591B (zh) * 2020-06-05 2024-01-05 山东大学 一种hdac、jak和bet三靶点抑制剂及其制备方法和应用
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
IL300248A (en) 2020-08-03 2023-03-01 Bicycletx Ltd peptide-based linkers
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
CN112225703B (zh) * 2020-09-28 2022-03-11 广州智睿医药科技有限公司 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
US12331046B2 (en) 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
CN114426542B (zh) * 2020-10-29 2023-06-30 苏州亚宝药物研发有限公司 取代的二芳基胺化合物及其药物组合物、制备方法和用途
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
EP4255895A1 (en) 2020-12-02 2023-10-11 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
JP2024501640A (ja) 2020-12-16 2024-01-15 インパクト バイオメディシンズ インコーポレイテッド フェドラチニブの投薬
WO2022143628A1 (zh) * 2020-12-29 2022-07-07 上海岸阔医药科技有限公司 预防或治疗抗肿瘤剂相关疾病或病症的方法
PH12023500015A1 (en) 2020-12-30 2024-03-11 Kymera Therapeutics Inc Irak degraders and uses thereof
CN112778282B (zh) * 2021-01-06 2022-07-22 温州医科大学 一种嘧啶类小分子化合物及其应用
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
EP4288427A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CN117120090A (zh) 2021-02-12 2023-11-24 林伯士萨顿公司 Hpk1拮抗剂和其用途
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
MX2023009858A (es) 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
EP4301756A4 (en) 2021-03-05 2025-02-26 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117355304A (zh) * 2021-03-26 2024-01-05 住友制药肿瘤公司 Alk-5抑制剂及其用途
WO2022203466A1 (ko) * 2021-03-26 2022-09-29 주식회사 스탠다임 Lrrk2에 대해 저해 활성을 갖는 신규한 페닐아미노피리미딘 화합물 및 이의 용도
CA3213359A1 (en) * 2021-03-26 2022-09-29 Bettina FRANZ Alk-5 inhibitors and uses thereof
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
AU2022256074A1 (en) 2021-04-09 2023-11-02 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024514879A (ja) 2021-04-16 2024-04-03 イケナ オンコロジー， インコーポレイテッド Ｍｅｋ阻害剤及びその使用
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
WO2023044297A1 (en) 2021-09-14 2023-03-23 Impact Biomedicines, Inc. Fedratinib for treating myeloproliferative disorders
WO2023043630A1 (en) * 2021-09-16 2023-03-23 Lomond Therapeutics, Inc. Compounds having n-arylpyrimidin-2-amine derivatives as therapeutic agents
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
EP4238564A1 (en) * 2022-03-02 2023-09-06 Bash Biotech Inc New treatments of renal cell carcinoma
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
IL316768A (en) 2022-05-25 2025-01-01 Ikena Oncology Inc MEK inhibitors and their uses
JP2025527247A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
IL318575A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
CN120051456A (zh) 2022-08-02 2025-05-27 里米诺生物科学有限公司 取代的吡啶酮gpr84拮抗剂及其用途
CN115745896B (zh) * 2022-11-18 2024-08-06 合肥医工医药股份有限公司 一种jak2激酶选择性抑制剂及其制备方法和用途
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2024179699A1 (en) * 2023-03-02 2024-09-06 Bash Biotech Inc. New compounds and treatment of renal cell carcinoma
IL321486A (en) 2023-06-23 2025-08-01 Kymera Therapeutics Inc Iraqi joints and their uses
WO2025062372A1 (en) 2023-09-21 2025-03-27 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease

Family Cites Families (231)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2A (en) * 1826-12-15 1836-07-29 John Goulding Mode of manufacturing wool or other fibrous materials
US2003199A (en) 1930-05-31 1935-05-28 Johnson Frank James Automatic coal stoker
US2003149A (en) 1931-05-22 1935-05-28 Autographic Register Co Manifolding
US2003065A (en) 1931-06-20 1935-05-28 John R Ditmars Composition for coating sheets, fibrous stocks, and the like
US2004102A (en) 1932-02-24 1935-06-11 Daniel A Dickey Hollow steel propeller construction
US2004138A (en) 1932-11-30 1935-06-11 Byers A M Co Method of making wrought iron pipe
US2002165A (en) 1933-07-08 1935-05-21 Charles A Winslow Air cleaner
US2003187A (en) 1933-10-02 1935-05-28 Frederick H Shaw Automobile radio device
US2003166A (en) 1933-10-26 1935-05-28 Zancan Ottavio Front drive for motor cars
US2001051A (en) 1933-12-01 1935-05-14 Angelina Mariani Tamperproof meter box with cutout control and fuse drawer for electric meters
US2004092A (en) 1933-12-15 1935-06-11 John L Chaney Device for indicating the temperature of liquids
US2003060A (en) 1934-04-02 1935-05-28 Ernest L Heckert Thermostatic controlling device
US2667486A (en) 1951-05-24 1954-01-26 Research Corp 2,4-diamino pteridine and derivatives
IL44058A (en) 1973-02-02 1978-10-31 Ciba Geigy Ag 3amino-1,2,4-benzotriazine 1,4-di-noxide derivatives, their preparation and compositions for the control of microorganisms containing them
AU535258B2 (en) 1979-08-31 1984-03-08 Ici Australia Limited Benzotriazines
DE3205638A1 (de) 1982-02-17 1983-08-25 Hoechst Ag, 6230 Frankfurt Trisubstituierte pyrimidin-5-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US4490289A (en) 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
DE3518887C1 (de) 1985-05-25 1986-09-18 Ernst Leitz Wetzlar Gmbh, 6330 Wetzlar Verfahren und Anordnung zur automatischen Bestimmung und Einstellung von Aufnahmeparametern bei einer fotografischen Aufnahmekamera
US5624925A (en) 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
JPH0741461B2 (ja) 1987-06-01 1995-05-10 株式会社日立製作所 剪断機
JP2598100B2 (ja) 1988-08-31 1997-04-09 キヤノン株式会社 電子写真感光体
US5214059A (en) 1989-07-03 1993-05-25 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
US5665543A (en) 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
GB9003553D0 (en) 1990-02-16 1990-04-11 Ici Plc Herbicidal compositions
JP2839106B2 (ja) 1990-02-19 1998-12-16 キヤノン株式会社 電子写真感光体
JPH03127790U (https=) 1990-04-06 1991-12-24
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
IE74711B1 (en) 1990-07-27 1997-07-30 Ici Plc Fungicides
GB9016800D0 (en) 1990-07-31 1990-09-12 Shell Int Research Tetrahydropyrimidine derivatives
DE4025891A1 (de) 1990-08-16 1992-02-20 Bayer Ag Pyrimidyl-substituierte acrylsaeureester
HK1001951A1 (en) * 1991-05-03 1998-07-24 Raisio Benecol Ltd. A substance for lowering high cholesterol level in serum and a method for preparing the same
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
HUT63941A (en) 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
US5438130A (en) 1993-01-15 1995-08-01 Cambridge Neuroscience, Inc. Fucosylated guanosine disulfates as excitatory amino acid antagonists
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5530000A (en) 1993-12-22 1996-06-25 Ortho Pharmaceutical Corporation Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
CA2230894A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0895475A4 (en) 1995-12-29 2000-08-23 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
JPH09274290A (ja) 1996-02-07 1997-10-21 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料用の現像液および処理方法
EP0939632B1 (en) 1996-02-23 2005-10-05 Eli Lilly And Company NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS
DE59707681D1 (de) 1996-10-28 2002-08-14 Rolic Ag Zug Vernetzbare, photoaktive Silanderivate
ES2278399T3 (es) 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
JP3734903B2 (ja) 1996-11-21 2006-01-11 富士写真フイルム株式会社 現像処理方法
JPH10153838A (ja) 1996-11-22 1998-06-09 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JP3720931B2 (ja) 1996-11-26 2005-11-30 富士写真フイルム株式会社 ハロゲン化銀写真感光材料の処理方法
US5935383A (en) 1996-12-04 1999-08-10 Kimberly-Clark Worldwide, Inc. Method for improved wet strength paper
BR9713842A (pt) 1996-12-04 2000-10-31 Kimberly Clark Co Método para fabricar papel com resistência úmida
CA2276034A1 (en) 1996-12-23 1998-07-02 Mimi Lifen Quan Oxygen or sulfur containing 5-membered heteroaromatics as factor xa inhibitors
JPH10207019A (ja) 1997-01-22 1998-08-07 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JPH10213820A (ja) 1997-01-31 1998-08-11 Canon Inc 液晶素子及び液晶装置
DE59807348D1 (de) 1997-02-05 2003-04-10 Rolic Ag Zug Photovernetzbare Silanderivate
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JPH10260512A (ja) 1997-03-19 1998-09-29 Fuji Photo Film Co Ltd ハロゲン化銀感光材料の処理方法
JPH10310583A (ja) 1997-05-09 1998-11-24 Mitsubishi Chem Corp ピリドンアゾ系化合物、感熱転写用色素およびそれを使用した感熱転写材料
US6070126A (en) 1997-06-13 2000-05-30 William J. Kokolus Immunobiologically-active linear peptides and method of identification
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
IL136637A0 (en) 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
US6685938B1 (en) 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US6136971A (en) 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
ES2274634T3 (es) * 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
BR9914164A (pt) 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
BR9914167B1 (pt) 1998-09-29 2011-03-09 compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
WO2000046203A2 (en) 1999-02-04 2000-08-10 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
PL215901B1 (pl) * 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
AU776962B2 (en) 1999-04-21 2004-09-30 Wyeth Holdings Corporation Substituted 3-cyano-(1.7), (1.5), and (1.8)-naphthyridine inhibitors of tyrosine kinases
WO2000071536A1 (en) 1999-05-20 2000-11-30 E.I. Du Pont De Nemours And Company Heteroaryloxypyrimidine insecticides and acaricides
JP4609691B2 (ja) 1999-07-01 2011-01-12 味の素株式会社 複素環化合物及びその医薬用途
WO2001007027A2 (en) 1999-07-22 2001-02-01 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives for the treatment of viral diseases
WO2001007032A1 (en) 1999-07-23 2001-02-01 Shionogi & Co., Ltd. Th2 differentiation inhibitors
WO2001007401A1 (en) 1999-07-23 2001-02-01 Shionogi & Co., Ltd. Tricyclic compounds and drug compositions containing the same
PL353267A1 (en) 1999-08-12 2003-11-03 American Cyanamid Company Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
US6093838A (en) 1999-08-16 2000-07-25 Allergan Sales, Inc. Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6127382A (en) 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7087597B1 (en) 1999-10-12 2006-08-08 Takeda Pharmaceutical Company Limited Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
WO2001032628A1 (en) 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
CA2396579A1 (en) 1999-12-29 2001-07-05 Wyeth Tricyclic protein kinase inhibitors
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
US6977259B2 (en) 2000-01-28 2005-12-20 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
US6153752A (en) 2000-01-28 2000-11-28 Creanova, Inc. Process for preparing heterocycles
US20020165244A1 (en) 2000-01-31 2002-11-07 Yuhong Zhou Mucin synthesis inhibitors
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
JP4064671B2 (ja) 2000-02-25 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
US6605615B2 (en) 2000-03-01 2003-08-12 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2001237401B2 (en) 2000-03-01 2006-11-09 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
JP2001247411A (ja) 2000-03-09 2001-09-11 Tomono Agrica Co Ltd 有害生物防除剤
KR100817423B1 (ko) 2000-03-13 2008-03-27 와이어쓰 홀딩스 코포레이션 시아노퀴놀린을 포함하는 결장 폴립의 치료 또는 억제를 위한 약제학적 조성물
US6613917B1 (en) 2000-03-23 2003-09-02 Allergan, Inc. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
AR028261A1 (es) 2000-03-28 2003-04-30 Wyeth Corp Inhibidores triciclicos de la proteina quinasa
CN1431896A (zh) 2000-04-04 2003-07-23 盐野义制药株式会社 含有高脂溶性药物的油性组合物
WO2001076582A1 (fr) 2000-04-05 2001-10-18 Shionogi & Co., Ltd. Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci
FR2808163B1 (fr) * 2000-04-19 2002-11-08 Celes Dispositif de chauffage par induction a flux transverse a circuit magnetique de largeur variable
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
DE10024622A1 (de) 2000-05-18 2001-11-22 Piesteritz Stickstoff N-(2-Pyrimidinyl)(thio)phosphorsäuretriamide, Verfahren zu ihrer Herstellung und deren Verwendung als Mittel zur Regulierung bzw. Hemmung der enzymatischen Harnstoff-Hydrolyse
EP1170353B1 (en) 2000-07-06 2005-11-02 Fuji Photo Film Co., Ltd. Liquid crystal composition comprising liquid crystal molecules and aligment promoter
JP5000068B2 (ja) 2000-08-11 2012-08-15 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チロシンキナーゼのインヒビターとして有用な複素環化合物
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1578341A2 (en) 2000-10-11 2005-09-28 Tularik Inc. Modulation of ccr4 function
EP1337513A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
EP1337524A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB Substituted quinolines as antitumor agents
EP1351686A2 (en) 2000-11-20 2003-10-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
WO2002053101A2 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
EP1353674A1 (en) 2000-12-29 2003-10-22 Alteon, Inc. Method for treating glaucoma ivb
JP2002221770A (ja) 2001-01-24 2002-08-09 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料およびその処理方法
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
PL364625A1 (en) 2001-02-23 2004-12-13 Merck & Co, Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
WO2002076438A2 (en) 2001-03-23 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
MXPA03009378A (es) 2001-04-13 2004-01-29 Vertex Pharma Inhibidores de cinasas c-jun n-terminales (jnk) y otras proteinas cinasas.
NZ528961A (en) * 2001-04-20 2005-04-29 Bayer Cropscience Ag Novel insecticidal azoles
WO2002090347A1 (en) 2001-04-30 2002-11-14 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
WO2002092087A1 (en) 2001-05-11 2002-11-21 Vertex Pharmaceuticals Incorporated 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
WO2002094766A1 (en) 2001-05-18 2002-11-28 Nihon Nohyaku Co., Ltd. Phthalamide derivative, agricultural or horticultural insecticide, and use thereof
WO2002096903A2 (fr) 2001-05-28 2002-12-05 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
CA2449054C (en) 2001-05-30 2011-01-04 The Scripps Research Institute Integrin targeting liposome for nucleic acid delivery
WO2003004492A1 (en) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
US6861529B2 (en) 2001-07-06 2005-03-01 Pfizer Inc Cycloalkypyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
DE10150610A1 (de) 2001-10-12 2003-04-30 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Amidbasen
DE10150614A1 (de) 2001-10-12 2003-04-30 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen
DE10150615A1 (de) 2001-10-12 2003-04-30 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
CA2463821A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
MXPA04004178A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
PL370137A1 (en) 2001-11-27 2005-05-16 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of egf-r and her2 kinases
JP2005510564A (ja) 2001-11-28 2005-04-21 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030166932A1 (en) 2002-01-04 2003-09-04 Beard Richard L. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US7910586B2 (en) 2002-01-04 2011-03-22 The Rockefeller University Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2475141A1 (en) 2002-02-05 2003-08-14 Wyeth Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids
AU2003220970A1 (en) 2002-03-01 2003-09-16 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
ES2445208T3 (es) * 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
CA2494695C (en) 2002-08-02 2011-04-05 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
MXPA05001804A (es) 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
DE10240262A1 (de) 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Aryllithium-Basen
DE10240261A1 (de) 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen
KR20120032574A (ko) 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
US20050282814A1 (en) 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
CA2500368A1 (en) 2002-10-04 2004-04-22 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization
US20040132732A1 (en) 2002-10-21 2004-07-08 Wei Han Quinazolinones and derivatives thereof as factor Xa inhibitors
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
EP1562938B1 (en) 2002-11-04 2007-08-29 Vertex Pharmaceuticals Incorporated Heteroaryl-pyrimidine derivatives as jak inhibitors
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
CA2508601A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
JP3837670B2 (ja) 2002-12-12 2006-10-25 富士通株式会社 データ中継装置、連想メモリデバイス、および連想メモリデバイス利用情報検索方法
MXPA05006732A (es) 2002-12-20 2005-09-08 Pharmacia Corp El isomero r de compuesto de beta-aminoacido como derivados de antagonistas de receptor de la integrina.
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
JP2006512387A (ja) 2002-12-24 2006-04-13 アストラゼネカ アクチボラグ 化合物
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
AP2005003365A0 (en) 2003-02-07 2005-09-30 Janssen Pharmaceutica Nv Hiv inhibiting 1, 2, 4-triazines.
BRPI0407329A (pt) 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv
US20040248850A1 (en) 2003-02-11 2004-12-09 Kemia, Inc. Compounds for the treatment of HIV infection
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1623269B2 (en) 2003-04-24 2022-08-31 CooperVision International Limited Hydrogel contact lenses and package systems and production methods for same
BRPI0413018B8 (pt) * 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
NZ585188A (en) * 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
MXPA06003054A (es) 2003-09-18 2006-05-31 Novartis Ag 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
KR20070011458A (ko) * 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
US7210697B2 (en) 2004-12-16 2007-05-01 Tricam International, Inc. Convertible handle
AU2005322855B2 (en) * 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US20060247250A1 (en) 2005-03-16 2006-11-02 Targegen, Inc. Pyrimidine inhibitors of kinases
US7389455B2 (en) * 2005-05-16 2008-06-17 Texas Instruments Incorporated Register file initialization to prevent unknown outputs during test
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ563984A (en) 2005-06-08 2011-11-25 Targegen Inc Methods and compositions for the treatment of ocular disorders
WO2006137658A1 (en) 2005-06-20 2006-12-28 Dongbu Hitek Co., Ltd. New substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppression and inflammation inhibitory acitivity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and pharmaceutical composition comprising the same
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
US20070072682A1 (en) 2005-09-29 2007-03-29 Crawford James T Iii Head to head electronic poker game assembly and method of operation
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US20070149508A1 (en) 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
US7803806B2 (en) 2005-11-03 2010-09-28 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
NZ568325A (en) 2005-11-16 2011-05-27 S Bio Pte Ltd Macrocyclic oxygen linked pyrimidine derivatives
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
CA2642229C (en) * 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7691858B2 (en) 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
US8030487B2 (en) * 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
MX2009000769A (es) 2006-07-21 2009-01-28 Novartis Ag Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak.
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
US20100016218A1 (en) 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
MX2011001426A (es) 2008-08-05 2011-03-21 Targegen Inc Metodos para tratar la talasemia.
ES2536276T3 (es) 2008-12-11 2015-05-22 Cti Biopharma Corp. Sal maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263

Similar Documents

Publication Publication Date Title
JP2013056930A5 (https=)
JP2009513703A5 (https=)
JP2021502387A5 (https=)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CN114174303B (zh) 作为sting激动剂的大环化合物及其方法和用途
RU2468021C2 (ru) Гетероциклические соединения и их применение
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
JP2019517487A5 (https=)
RU2013144571A (ru) Алинзамещенные хиназолины и способы их применения
JP2016519653A5 (https=)
JP2009536620A5 (https=)
JP2014518544A5 (https=)
JP2018519245A5 (https=)
JP2018516238A5 (https=)
JP2016513661A5 (https=)
JP2013010792A5 (https=)
JP2019518766A5 (https=)
JP2016518324A5 (https=)
WO2016082713A1 (zh) 2-氨基嘧啶类化合物及其药物组合物和应用
RU2016101548A (ru) Соединения амидов гетероарилпиридона и азапиридона
JP2020536971A5 (https=)
JP2016506387A5 (https=)
RU2003114740A (ru) Азотсодержащие ароматические производные
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
RU2015143542A (ru) Ингибиторы jak2 и alk2 и способы их использования